CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting

Neutral
AI Analysis

Summary

Novo announced a $23B revenue target by 2035 and is pursuing acquisitions to address pipeline gaps across obesity, diabetes, blood and endocrine disorders, liver diseases, and cardiovascular conditions. Investors expressed disappointment with the plan.

Financial Highlights

Revenue

$23B by 2035

Guidance

$23B revenue target by 2035

Importance:3/10
Sentiment:
-0.20
pipeline strategyM&Aobesitydiabetesrevenue guidance

Read the original article

Published by BioSpace on September 21, 2026 2:36 PM

Read Original